Search company, investor...
Search

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

ascendancebio.com

Stage

Acquired | Acquired

Total Raised

$880K

About Ascendance Biotechnology

Ascendance Biotechnology is formed by BioTime and Hepregen Corporation to address the In Vitro cell biology market. Ascendance combines Hepregen's application-directed, cellular micro-patterning drug and chemical screening technologies with BioTime's ESI BIO research products and proprietary stem cell technologies. This asset combination will allow Ascendance to offer a broad portfolio of current and new stem-cell-derived assays and other products and services to Hepregen's major pharmaceutical and chemical company customers.

Ascendance Biotechnology Headquarters Location

200 Boston Avenue Suite 1500

Medford, Massachusetts, 02155,

United States

781-391-0205

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Ascendance Biotechnology

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Ascendance Biotechnology is included in 2 Expert Collections, including Regenerative Medicine.

R

Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

B

Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Ascendance Biotechnology Patents

Ascendance Biotechnology has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

1/26/2016

6/30/2020

Clusters of differentiation, Transcription factors, Cell biology, Human cells, Immunology

Grant

Application Date

1/26/2016

Grant Date

6/30/2020

Title

Related Topics

Clusters of differentiation, Transcription factors, Cell biology, Human cells, Immunology

Status

Grant

Latest Ascendance Biotechnology News

Hepregen Corporation (Ascendance Biotechnology)

Jun 24, 2020

MIT Deshpande Center 2008 | Healthcare Hepregen Corporation is developing bioengineered solutions for drug development, including a platform for advanced toxicity screening and drug discovery. With its high fidelity model of the human liver, Hepregen's bioengineered solution may provide improved predictivity of how drugs will affect the liver once in humans. For the story of the Deshpande Center project that became Hepregen Corporation, see Case Studies . This company is a spinout of the 2006 project , Human liver models for faster, safer drug development.

  • Where is Ascendance Biotechnology's headquarters?

    Ascendance Biotechnology's headquarters is located at 200 Boston Avenue, Medford.

  • What is Ascendance Biotechnology's latest funding round?

    Ascendance Biotechnology's latest funding round is Acquired.

  • How much did Ascendance Biotechnology raise?

    Ascendance Biotechnology raised a total of $880K.

  • Who are the investors of Ascendance Biotechnology?

    Investors of Ascendance Biotechnology include BioIVT and Lineage Cell Therapeutics.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.